Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Fiche publication
Date publication
novembre 2021
Journal
Blood advances
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DRENOU Bernard
Tous les auteurs :
Bagacean C, Letestu R, Al-Nawakil C, Brichler S, Lévy V, Sritharan N, Delmer AJ, Dartigeas C, Leblond V, Roos-Weil D, Tomowiak C, Merabet F, Béné MC, Clavert A, Chaoui D, Genet P, Guieze R, Laribi K, Drénou B, Willems L, Puppinck C, Legendre H, Troussard X, Malartre S, Cymbalista F, Michallet AS
Lien Pubmed
Résumé
Immunocompromised individuals such as chronic lymphocytic leukemia (CLL) patients are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate SARS-CoV-2-specific antibody responses in CLL patients, after the first, second and third doses of the BNT162b2 and mRNA-1273, and after a single dose for patients with confirmed prior COVID-19. Five hundred and thirty patients were included in the study. Patients received 2 doses at a 4-week interval, and a third dose if seronegative after the second dose. Response rate was 27% post-dose 1 and 52% post-dose 2. Post-dose 2 treatment-naïve patients had the highest response rate (72%) followed by patients previously treated by chemoimmunotherapy (60%). Among patients on therapy, patients on BTKi alone (22%) or in combination with anti-CD20 monoclonal antibodies or venetoclax (0%) had the poorer response rate whereas patients on venetoclax monotherapy achieved a significantly higher response rate (52%). A multivariate analysis identified as independent predictors of the absence of seroconversion: age >65 years, ongoing CLL treatment and gamma-globulins ≤6g/L. Post-dose 2 seronegative patients had a global post-dose 3 response rate of 35%. This study provides an argument for the use of a third dose and for prophylactic SARS-CoV-2 neutralizing monoclonal antibodies.
Référence
Blood Adv. 2021 Nov 29;: